CRESCENT BIOPHARMA, INC. — Director's Dealing 2015

Nov 18, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2015-11-16

Reporting Person: NEW ENTERPRISE ASSOCIATES 10 L P (10% Owner)
Reporting Person: NEA PARTNERS 10 L P (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-11-16	Common Stock	X	9445	$0.33	Acquired	4491203	Direct
2015-11-16	Common Stock	S	452	$6.91	Disposed	4490751	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-11-16	Warrant to Purchase Common Stock (right to buy)	$0.33	X	9445	Disposed	2015-12-09	Common Stock (9445)	Direct

Footnotes

F1: The shares are directly held by New Enterprise Associates 10, Limited Partnership ("NEA 10") and indirectly held by NEA Partners 10, Limited Partnership ("NEA Partners 10"), the sole general partner of NEA 10, and the individual general partners of NEA Partners 10 (NEA Partners 10 and its individual general partners together, the "Indirect Reporting Persons"). The individual general partners of NEA Partners 10 are Peter J. Barris, M. James Barrett and Scott D. Sandell. Each Indirect Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 10 shares in which such Indirect Reporting Person has no pecuniary interest.

F2: On November 16, 2015, NEA 10 exercised warrants to purchase a total of 9,445 shares of the Issuer's common stock for $0.33 a share. NEA 10 paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 452 of the warrant shares to pay the exercise price and issuing 8,993 shares to NEA 10. The Issuer also paid cash to NEA 10 in lieu of any fractional shares to be issued upon exercise of the warrants.